A point-of-need platform for rapid measurement of a host-protein score that differentiates bacterial from viral infection: Analytical evaluation

• Published in: Clinical biochemistry Vol. 117; pp. 39 - 47
• Main Authors: Hainrichson, Mary, Avni, Noa, Eden, Eran, Feigin, Paul, Gelman, Amir, Halabi, Salim, Hartog-David, Efrat, Hulten, Kristina G., Jalal, Ashkar, Kalfon, Roy, Lamberth, Linda, Lewis, Shawna, Navon, Roy, Oved, Kfir, Raz-Pasteur, Ayelet, Senderovich, Naftalie, Shaham, Oded, Shraga, Meytal, Simon, Einav, Sommer, Lauren M., Zarchin, Oren, Carroll, Karen C., Gottlieb, Tanya M.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.07.2023
• Subjects: C-Reactive Protein; Chemiluminescence; Chemokine CXCL10; CRP; Humans; IP-10; MeMed BV; MeMed Key; Rapid immunoassay platform; Reproducibility of Results; TRAIL; Virus Diseases - diagnosis; CRP; LLoQ; SD; MeMed BV; TRAIL; CV; MeMed Key; Chemiluminescence; IP-10; EC; ELISA; Rapid immunoassay platform
• ISSN: 0009-9120; 1873-2933
• DOI: 10.1016/j.clinbiochem.2022.04.012

The objective was to evaluate the analytical performance of a new point-of-need platform for rapid and accurate measurement of a host-protein score that differentiates between bacterial and viral infection. The system comprises a dedicated test cartridge (MeMed BV®) and an analyzer (MeMed Key®). In each run, three host proteins (TRAIL, IP-10 and CRP) are measured quantitatively and a combinational score (0–100) computed that indicates the likelihood of Bacterial versus Viral infection (BV score). Serum samples collected from patients with acute infection representing viral (0 ≤ score < 35), equivocal (35 ≤ score ≤ 65), or bacterial (65 < score ≤ 100) scores based on pre-defined score cutoffs were employed for the analytical evaluation studies as well as samples from healthy individuals. To assess reproducibility, triplicate runs were conducted at 3 different sites, on 2 analyzers per site over 5 non-consecutive days. Lower limit of quantitation (LLoQ) and analytical measurement range were established utilizing recombinant proteins. Sample stability was evaluated using patient samples representative of BV score range (0–100). MeMed Key® and MeMed BV® passed the acceptance criteria for each study. In the reproducibility study, TRAIL, IP-10 and CRP measurements ranged with coefficient of variation from 9.7 to 12.7%, 4.6 to 6.2% and 5.0 to 11.6%, respectively. LLoQ concentrations were established as 15 pg/mL, 100 pg/mL and 1 mg/L for TRAIL, IP-10 and CRP, respectively. In summary, the analytical performance reported here, along with diagnostic accuracy established in the Apollo clinical validation study (NCT04690569), supports that MeMed BV® run on MeMed Key® can serve as a tool to assist clinicians in differentiating between bacterial and viral infection.